GlassScriptPhysician profile
Robert M Schwartz
NPI 1205832581
$3,289.56
in general payments reported to CMS, 2019-2025
12 companies · $252 in 2025
The $252 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $366 · 2020: $473 · 2021: $473 · 2022: $589 · 2023: $595 · 2024: $541 · 2025: $252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,291 · Education: $98.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,290.82 |
| Education | $98.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,183.02 | 2019-2025 | Stelara, Tremfya, Simponi |
| Abbvie INC. | $311.70 | 2019-2025 | Rinvoq |
| Ironwood Pharmaceuticals, INC | $297.01 | 2019-2025 | Linzess |
| Cook Medical LLC | $109.38 | 2024 | Hemospray |
| Takeda Pharmaceuticals U.S.A., INC. | $95.00 | 2019-2024 | Entyvio, Eohilia |
| W. L. Gore & Associates, INC. | $94.20 | 2019 | |
| Celltrion USA INC. | $69.07 | 2024 | Zymfentra |
| Celgene Corporation | $61.25 | 2021-2022 | |
| Pfizer INC. | $21.50 | 2024 | |
| Boston Scientific Corporation | $18.73 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $16.25 | 2025 | Simlandi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.